Q-omics provides the consensus-scored MIR5092 profile across patient tissues and cancer cell-line models. MIR5092 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR5092 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR5092 RNA expression shows 9,545 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight READ, KIRC, and HNSC as cancer lineages where MIR5092 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5092 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5092 survival associations across molecular data types. MIR5092 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5092 RNA expression–survival associations across cancer types. High MIR5092 expression shows unfavorable associations in READ, KIRC, LUSC, DLBC and THYM, but favorable associations in OV. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR5092 RNA expression.
This table summarizes MIR5092 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5092. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5092 shows lower tumor expression in LUSC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher MIR5092 RNA expression in tumor versus normal tissue (log2 FC = +0.254, t-test p = .014).
This table shows molecular features associated with MIR5092 in patient tissues and cancer cell lines. In patient samples, MIR5092 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
